EMEA-000980-PIP01-10-M07
Key facts
| Invented name |
Adcetris
|
| Active substance |
Brentuximab vedotin
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0013/2021
|
| PIP number |
EMEA-000980-PIP01-10-M07
|
| Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Takeda Pharma A/S
Tel. +45(0) 46771111 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000980-PIP01-10-M07
|
| Compliance opinion date |
25/06/2021
|
| Compliance outcome |
positive
|